(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Experts who once backed 'shaken baby' science now fight to free imprisoned caregivers - 2The Drone Video of the Year is stunning – you've not seen Namibia like this
- 3Purchases of iPhone 17 Pro soar across Gaza amid 'limited' humanitarian aid
- 4Shas threatens to oppose 2026 state budget over haredi food-voucher exclusion
- 5Nine in 10 German industrial firms expect Iran war to hit business
- The Best Computer games Ever
- Hoist Your Style: Famous Hairdos for Ladies
- Vote in favor of your Favored Travel Movement
- Kennedy approves adding two rare disorders to newborn screenings
- 10 Distinct Kinds of Chinese Neighborhood Specialty Hot Pot
- James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- Which Switch Game Do You Suggest? Share Your Decision
- The most effective method to Succeed in Your Web based Advertising Degree: Procedures for Progress
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
